ARS Pharmaceuticals (SPRY) Amortizatization of Intangibles (2020 - 2026)

ARS Pharmaceuticals has disclosed Amortizatization of Intangibles across 7 years of filings, most recently posting $990000.0 for Q1 2026.

• Amortizatization of Intangibles for Q1 2026 came in at $990000.0, down 49.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 million (down 59.34% YoY), and the FY2025 annual result was $5.5 million, down 23.86% from the prior year.
• Amortizatization of Intangibles came in at $990000.0 for Q1 2026 at ARS Pharmaceuticals, down from $1.0 million in the prior quarter.
• In the past five years, Amortizatization of Intangibles ranged from a high of $5.9 million in Q2 2024 to a low of -$2.0 million in Q1 2024.
• The 5-year median for Amortizatization of Intangibles is $996500.0 (2025), against an average of $514571.4.
• Across the five-year window, Amortizatization of Intangibles sank 705.96% in 2023 and jumped 434.7% in 2024, its largest moves.
• ARS Pharmaceuticals' Amortizatization of Intangibles stood at $285000.0 in 2022, then sank by 705.96% to -$1.7 million in 2023, then jumped by 189.4% to $1.5 million in 2024, then slumped by 35.04% to $1.0 million in 2025, then dropped by 1.3% to $990000.0 in 2026.
• The last three Amortizatization of Intangibles figures came in at $990000.0 (Q1 2026), $1.0 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.